Trump administration has not reset the large pharmaceutical pressure campaign

In its campaign, the Trump administration has relentlessly to reduce drug prices and to move the pharmaceutical industry's supply chain. On Thursday, a special advisor from the Trump administration doubled in relation to both goals of the administration.

Calley means, special advisor of the HHS secretary Robert F. Kennedy Jr., said that Trump does not try to hire certain pricing, but will continue to pursue the administration in accordance with Europe – but will no longer prescribe a certain price.

“I really don't think it is the role of the government to say what the price should be. We just don't want to pay more than other industrialized countries,” says a common US pharmaceutical and Biotech summit, which is organized by the Financial Times and Endpoints News in New York.

He also had a message for companies such as Roche (Rhhby), which threatens to draw billions of manufacturing obligations: “This is morally reprehensible. Keep on and do it.”

He added: “To keep an economic weapon on the head when this administration tries to achieve the urgent goal of reverse the existential crisis of chronic diseases and the existential budget crisis … and try to try an economic argument with this, completely unacceptable …”

The administration has already raised a few tariffs that have medical devices, and threatens a custom of around 20% for medication that was produced outside the USA. In addition, Trump signed an Executive Order (EO) this week, which is referred to as the highest -privileged nation and would force companies to sell treatments in the United States at the same price as the lowest in a developed nation.

Before the EO, the manufacturers announced tens of billions of dollars of obligations for Onshore production and other parts of the supply chain, which sensed the former administration of Trump for inspiration for these efforts in 2020.

Together with Johnson & Johnson (JNJ), Roche proposed one of the greatest obligations with 55 billion US dollars, $ 50 billion, and Eli Lilly (Lly), who have signed 27 billion US dollars for a total of $ 50 billion.

After the EO, Astrazeneca (AZN) chose an middle path.

“We share President Trump's commitment to ensure that the costs for pharmaceutical innovation under high income nations are quite shared,” says a statement on Monday.

“A most preferred prize policy of the nation would have to be implemented with thorough stakeholder engagement and robust systems in order to avoid the disorder of patient care, undermine the US leadership in biotechnology and suppress the innovation that drives global health promotions.”